1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
S2Medical AB (publ)

S2Medical AB (publ)

S2M.ST
S2Medical AB (publ)SE flagStockholm Stock Exchange
0.01
SEK
+0.00
- -
4.85MMarket Cap
S2Medical AB (publ)
S2M.ST
(Stockholm Stock Exchange)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.01
0.03
0.02
0.05
0.43
0.14
0.04
0.02
0.03
0.02
0.04
Revenue per Share
-0.03
-0.16
-0.18
-0.32
-0.25
-0.36
-0.25
-0.08
0.01
-0.01
-0.01
Basic EPS, GAAP
-0.08
-0.19
-0.25
-0.35
-0.25
-0.41
-0.25
-0.06
0.01
- -
0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.05
-0.24
-0.32
-0.69
-0.93
0.02
0.02
-0.42
-0.18
-0.13
0.06
Book Value per Share
0.01
0.15
0.65
0.32
0.42
0.05
-0.04
-0.04
0.01
- -
-0.01
Tangible Book Value per Share
47
33
60
58
60
56
120
284
560
857
299
Basic Weighted Avg Shares
- -
1
1
3
26
8
5
7
15
14
11
Sales/Revenue/Turnover
-307.94
-619.2
-709.19
-591.73
-58.8
-257.62
-592.88
-218.95
32.89
-18.55
18.07
Operating Margin (%)
- -
1
1
1
1
1
2
2
1
1
2
Depreciation Expense
-1
-5
-11
-18
-15
-20
-29
-23
5
-10
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-351.47
-637.35
-717.5
-595
-59.08
-260.78
-630.73
-325.73
32.78
-70.28
-20.3
Profit Margin (%)
2
5
38
17
23
1
-6
-11
-1
-3
-2
Working Capital
- -
3
2
1
- -
- -
- -
- -
- -
- -
- -
LT Debt
3
7
44
25
33
15
7
2
19
10
10
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
46.54
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-4.39
- -
176.5
Return on Capital (%)
- -
- -
- -
- -
- -
- -
-2,115.44
-251.77
41.24
- -
-22.84
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
355
355
372
Market Capitalization
7
14
11

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
9
9
5
Cash, Cash Equivalents & STI
2
1
1
Accounts Receivable, Net
1
1
1
Inventories
4
4
1
Total Current Liabilities
20
19
7
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
159.56%
-47.25%
Free Cash Flow
- -
-42.42%
-126.8%
Net Income, GAAP
- -
-74.9%
-309.79%
Sales/Revenue/Turnover
- -
9.67%
-2.15%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1
1
1
2
7
2024
4
3
- -
- -
15
2025
7
- -
- -
- -
14

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.11
-0.16
-0.03
-0.01
-0.08
2024
- -
0.02
- -
- -
0.01
2025
- -
- -
- -
- -
-0.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Well Lead Medical Co., Ltd. (603309.SS)
Harvard Bioscience, Inc. (HBIO)
KMA Holding, Inc. (MCDA)
Tristel PLC (TSNLF)
G Medical Innovations Holdings Ltd (GMVD)
Shanghai Kindly Enterprise Development Group Co.,LTD. (603987.SS)
Business
S2Medical AB (publ) (S2M.ST) develops, manufactures and commercializes innovative medical technologies focused on wound healing for burns and chronic wounds, infection control and cosmeceuticals; core products include Epiprotect, a biosynthetic cellulose wound dressing now owned by Epiprotect AB within the ABENA Group with S2Medical retaining production involvement; IvaQ, a CE-marked single-use negative pressure wound therapy system; Instagraft, a patented skin micro-transplantation device increasing donor-to-transplant ratios up to 1:100; ADMERCIN, an antimicrobial peptide platform targeting multi-drug resistant ESKAPE pathogens and enhancing antibiotic efficacy; Symbiovance, peptide-based functional skincare for licensing; and Eyracure (22.3% owned), a light-activated BIOlap20 peptide for hair repair commercialized via partners like LYKO; the company also operates S2Clinic wound healing centers. Founded in 2013 and headquartered in Linköping, Sweden, S2Medical lists on Nasdaq First North Growth Market Stockholm and serves healthcare providers, hospitals and dermatology markets across Europe, Middle East, Asia and beyond through exclusive distribution agreements in countries including Saudi Arabia, Philippines, Georgia, Turkey, UAE and Malaysia. Recent developments encompass successful completion of corporate reconstruction in April 2024 enabling debt-free status by May 2024; an agreement with ABENA in February 2024 for Epiprotect commercialization projecting tripled sales in 2024; offensive rights issue of SEK 11.5 million in August 2024; acquisition of additional shares in Eyracure AB in August 2024; US patent approval for Plantaricin NC8 antimicrobial technology in October 2024; exclusive distribution deals for Biopad in Philippines and cosmetic formulations with Eyracure in 2024; procurement wins in Sweden's Region Stockholm and South Africa patent for Eyracure's BioLAP-20; alongside IvaQ market readiness for 2025 partnerships.